Wide Ranks

ICUCW

0.0271

Top Statistics
Market Cap 0.0000 Forward PE 0.0000 Revenue Growth 0.00 %
Current Ratio 0.24 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 1 M Total Cash Per Share 0.2830 Total Debt 3 M
Total Debt To Equity Current Ratio 0.24 Book Value Per Share -7.28
All Measures
Message Board Id finmb_111447 City Denver Uuid 47ef9d73-fb27-36a0-988d-ce3f39f647ed
Previous Close 0.0266 Book Value -7.28 Beta -1.06
Total Debt 3 M Volume 112016 Fifty Two Week Low 0.0271
Total Cash Per Share 0.2830 Max Age 86400 Sand P52 Week Change 0.3133
Net Income To Common -32622000 Trailing Peg Ratio None Total Cash 1 M
Trailing PE 0.0000 Regular Market Previous Close 0.0266 Target Low Price 0.0000
Gmt Off Set Milliseconds -18000000 Open 0.0285 Free Cashflow -5685250
State CO Dividend Yield 0.00 % Return On Assets -3.08
Time Zone Short Name EST Day Low 0.0271 Address1 3513 Brighton Boulevard
Target High Price 0.0000 Price Hint 4 Website https://www.seastarmedical.com
Forward Eps 0.0000 Recommendation Key none Compensation As Of Epoch Date 1 B
Quick Ratio 11.90 % Is_sp_500 False Regular Market Day High 0.0308
Profit Margins 0.00 % Fifty Two Week High 0.0308 Day High 0.0308
Regular Market Open 0.0285 Industry Key biotechnology Earnings Growth 0.00 %
Revenue Growth 0.00 % Operating Cashflow -12134000 Currency USD
Time Zone Full Name America/New_York Is_nasdaq_100 False Market Cap 0.0000
Zip 80216 Quote Type EQUITY Industry Biotechnology
Long Name SeaStar Medical Holding Corporation Regular Market Day Low 0.0271 Current Price 0.0271
Address2 Suite 410 Financial Currency USD Current Ratio 0.24
Industry Disp Biotechnology Country United States Float Shares 4 M
Forward PE 0.0000 Regular Market Volume 112016 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States.

The company offers inflammatory response to fend off infections and repair damaged tissue in the body.

It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome.

The company is headquartered in Denver, Colorado.